MedTrace Logo

Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI

NCT01642134 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2019-08-09

No results posted yet for this study

Summary

The purpose of this study is to determine the incidence of major vascular events (ischemic or haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral anticoagulation or dual antiplatelet therapy) in both arms followed TAVI.

Conditions

  • Aortic Valve Stenosis
  • Stroke

Interventions

DRUG

aspirin+clopidogrel (Duoplavin)

100 mg aspirin ;75 mg clopidogrel 3º months

Sponsors & Collaborators

  • Andres Iñiguez Romo, MD, PhD

    lead OTHER_GOV

Principal Investigators

  • Andres Iniguez Romo, MD;PHD · Hospital Universitario Alvaro Cunqueiro

  • Victor A. Jimenez Diaz, MD;Msc · Hospital clinico universitario Vigo

  • Mariano Larman Tellechea, MD · Policlínica de Guipuzcoa SA San Sebastián

  • Pablo Juan Salvadores, Pharma,MPH · Hospital Universitario Álvaro Cunqueiro

  • Jose M. Hernandez, MD · Hospital Virgen de la Victoria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01642134 on ClinicalTrials.gov